Dusseldorf - Delayed Quote EUR

Allakos Inc (37Z.DU)

0.2383

+0.0057

+(2.45%)

As of 4:30:14 PM GMT+1. Market Open.

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 2 days ago

BIOA

AKRO

VNDA
Allakos cuts 75% of workforce after chronic hives trial failure

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Pharmaceutical Technology 2 days ago

ALLK
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). “While AK006 was well tolerated, we are disappo

GlobeNewswire 4 days ago

ALLK
Discover US Penny Stocks To Watch In January 2025

As the U.S. stock market continues to rally, with major indices closing higher following President Trump's recent executive actions, investors are exploring diverse opportunities. Among these are penny stocks, which despite their name suggesting an outdated concept, remain a relevant area for investment consideration. Typically representing smaller or newer companies, penny stocks can offer growth potential and affordability when backed by strong financials.

Simply Wall St. 9 days ago

SES

SES-WS

WDH
3 US Penny Stocks Under $200M Market Cap To Watch

As the U.S. stock market experiences fluctuations, with technology shares recently sliding and major indices taking a breather from their record highs, investors are on the lookout for new opportunities. Penny stocks, often representing smaller or newer companies, might seem like a term from bygone trading days but continue to hold relevance due to their potential for growth when backed by strong fundamentals. This article will explore three such penny stocks that stand out for their...

Simply Wall St. 2 months ago

TOUR

BZUN

ALLK
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy

Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

ALLK
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of subcutaneous (SC) AK006 in healthy volunteers. Bio

GlobeNewswire 2 months ago

ALLK
3 US Penny Stocks With Market Caps Larger Than $50M

As investors digest a flurry of earnings reports, stock futures are pointing to a lower open for major U.S. indexes, reflecting the ongoing volatility and mixed sentiment in the market. For those exploring investment opportunities beyond the traditional large-cap stocks, penny stocks—despite their somewhat outdated name—remain an intriguing area due to their potential for growth and value. In this article, we examine several penny stocks that exhibit strong financial foundations, offering...

Simply Wall St. 3 months ago

DC

DC-WT

SMRT
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results fr

GlobeNewswire 3 months ago

ALLK
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Complet

GlobeNewswire 5 months ago

ALLK
Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 6 months ago

ALLK
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple asc

GlobeNewswire 7 months ago

ALLK
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and t

GlobeNewswire 8 months ago

ALLK
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions

Detailed Analysis of Financial Performance and Future Outlook

GuruFocus.com 8 months ago

ALLK
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled

GlobeNewswire 8 months ago

ALLK
With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners

Key Insights Institutions' substantial holdings in Allakos implies that they have significant influence over the...

Simply Wall St. 8 months ago

ALLK
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks 9 months ago

ALLK
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development Focus

GuruFocus.com 10 months ago

ALLK
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and continued dosing in the multiple ascending dose (MAD) cohorts of the r

GlobeNewswire 10 months ago

ALLK
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory an

GlobeNewswire 10 months ago

ALLK

Performance Overview

Return	37Z.DU	S&P 500
YTD	-81.02%	+3.43%
1-Year	-81.34%	+24.06%
3-Year	-95.71%	+37.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Allakos Inc (37Z.DU)

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

Allakos cuts 75% of workforce after chronic hives trial failure

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

Discover US Penny Stocks To Watch In January 2025

3 US Penny Stocks Under $200M Market Cap To Watch

All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

3 US Penny Stocks With Market Caps Larger Than $50M

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Performance Overview